NDC 60505-3252

LAMIVUDINE

Lamivudine

LAMIVUDINE is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Apotex Corp.. The primary component is Lamivudine.

Product ID60505-3252_3386ea26-be19-272d-a2b4-1414f9c6f614
NDC60505-3252
Product TypeHuman Prescription Drug
Proprietary NameLAMIVUDINE
Generic NameLamivudine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2011-12-02
Marketing CategoryANDA / ANDA
Application NumberANDA091606
Labeler NameApotex Corp.
Substance NameLAMIVUDINE
Active Ingredient Strength300 mg/1
Pharm ClassesHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 60505-3252-3

30 TABLET, FILM COATED in 1 BOTTLE (60505-3252-3)
Marketing Start Date2011-12-02
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 60505-3252-0 [60505325200]

LAMIVUDINE TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA091606
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2011-12-02
Marketing End Date2018-01-11

NDC 60505-3252-3 [60505325203]

LAMIVUDINE TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA091606
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-12-02

NDC 60505-3252-8 [60505325208]

LAMIVUDINE TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA091606
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2011-12-02

Drug Details

Active Ingredients

IngredientStrength
LAMIVUDINE300 mg/1

OpenFDA Data

SPL SET ID:34c02bcc-d6ff-99d4-8e6a-4a91908adca8
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 199147
  • 349491
  • Pharmacological Class

    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    Medicade Reported Pricing

    60505325203 LAMIVUDINE 300 MG TABLET

    Pricing Unit: EA | Drug Type:

    NDC Crossover Matching brand name "LAMIVUDINE" or generic name "Lamivudine"

    NDCBrand NameGeneric Name
    0904-6583LAMIVUDINElamivudine
    10135-605LamivudineLamivudine
    31722-001lamivudinelamivudine
    31722-752LamivudineLamivudine
    31722-753LamivudineLamivudine
    31722-754LamivudineLamivudine
    33342-001LamivudineLamivudine
    33342-002LamivudineLamivudine
    68180-603LamivudineLamivudine
    68180-602LamivudineLamivudine
    69097-167LAMIVUDINELAMIVUDINE
    69097-166LAMIVUDINELAMIVUDINE
    70518-0540LamivudineLamivudine
    70518-0440LamivudineLamivudine
    70518-0513LamivudineLamivudine
    70518-0690LamivudineLamivudine
    70518-1083LamivudineLamivudine
    70518-1084LamivudineLamivudine
    70518-1634LamivudineLamivudine
    70518-1933LamivudineLamivudine
    50268-460LamivudineLamivudine
    50268-459LamivudineLamivudine
    50742-623LamivudineLamivudine
    50742-624LamivudineLamivudine
    51293-832LamivudineLamivudine
    53808-0843LAMIVUDINELAMIVUDINE
    53808-0844LAMIVUDINELAMIVUDINE
    54838-566LamivudineLamivudine
    57237-274LamivudineLamivudine
    60429-354LAMIVUDINELAMIVUDINE
    60687-362LamivudineLamivudine
    60429-353LAMIVUDINELAMIVUDINE
    60505-3250LamivudineLamivudine
    60505-3252LAMIVUDINELAMIVUDINE
    60505-3251LAMIVUDINELAMIVUDINE
    63629-5014LamivudineLamivudine
    64380-711LamivudineLamivudine
    64330-001LamivudineLamivudine
    64380-710LamivudineLamivudine
    65862-055LamivudineLamivudine
    65862-026LamivudineLamivudine
    65862-552LamivudineLamivudine
    65862-553LamivudineLamivudine
    65862-025LamivudineLamivudine
    66993-478LamivudineLamivudine
    69967-003LamivudineLamivudine
    69967-004LamivudineLamivudine
    70518-2067LamivudineLamivudine
    70518-2070LamivudineLamivudine
    0173-0662EPIVIRlamivudine

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.